METHOD OF TREATING CANCER USING IMMUNE CHECKPOINT INHIBITOR
First Claim
1. A method for treating a subject afflicted with a tumor derived from a human papilloma virus (HPV)-positive squamous cell carcinoma head and neck cancer (SCCHN) comprising administering to the subject a therapeutically effective amount of:
- an antibody or antigen-binding portion thereof that binds specifically to a Programmed Death-1 receptor (PD-1) or Programmed Death-Ligand 1 (PD-L1) and inhibits PD-1 activity (“
anti-PD-1 antibody or antigen-binding portion thereof”
) or PD-L1 activity (“
anti-PD-L1 antibody or antigen-binding portion thereof”
), respectively.
1 Assignment
0 Petitions
Accused Products
Abstract
This disclosure provides a method for treating HPV-positive squamous cell carcinoma of the head and neck comprising administering to the subject an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody. The disclosure also provides a method for treating HPV-negative squamous cell carcinoma of the head and neck administering to the subject an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody. The subject can be additionally administered another anti-cancer agent.
-
Citations
39 Claims
-
1. A method for treating a subject afflicted with a tumor derived from a human papilloma virus (HPV)-positive squamous cell carcinoma head and neck cancer (SCCHN) comprising administering to the subject a therapeutically effective amount of:
an antibody or antigen-binding portion thereof that binds specifically to a Programmed Death-1 receptor (PD-1) or Programmed Death-Ligand 1 (PD-L1) and inhibits PD-1 activity (“
anti-PD-1 antibody or antigen-binding portion thereof”
) or PD-L1 activity (“
anti-PD-L1 antibody or antigen-binding portion thereof”
), respectively.- View Dependent Claims (5, 7, 11, 12, 14, 15, 16, 17, 18, 20, 22, 23, 27, 28, 32, 35, 36, 38)
-
2. A method of treating a subject afflicted with a tumor derived from an HPV-positive SCCHN comprising:
-
(i) measuring a level of HPV in a sample of the subject, wherein the subject is positive for HPV; and (ii) administering to the subject a therapeutically effective amount of an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof.
-
-
3-4. -4. (canceled)
-
6. (canceled)
-
8-10. -10. (canceled)
-
13. (canceled)
-
19. (canceled)
-
21. (canceled)
-
24-26. -26. (canceled)
-
29-31. -31. (canceled)
-
33-34. -34. (canceled)
-
37. (canceled)
-
39-80. -80. (canceled)
Specification